Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ) (CHEMPAQ)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01138618 |
Recruitment Status
:
Completed
First Posted
: June 7, 2010
Last Update Posted
: November 7, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Schizophrenia | Device: Venous blod sample Device: CHEMPAQ |
Study Type : | Observational |
Actual Enrollment : | 85 participants |
Observational Model: | Case-Crossover |
Time Perspective: | Prospective |
Official Title: | Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ) |
Study Start Date : | April 2010 |
Actual Primary Completion Date : | December 2010 |
Actual Study Completion Date : | May 2011 |

Group/Cohort | Intervention/treatment |
---|---|
CHEMPAQ-venous-CHEMPAQ-venous
The two arms only differ in order of kind of blood samples.
|
Device: Venous blod sample
Regular venous blood sample withdrawn from the laboratory
Device: CHEMPAQ
Capillary blood sample analyzed by CHEMPAQ
|
Venous-CHEMPAQ-Venous-CHEMPAQ
The two arms only differ in order of kind of blood samples.
|
Device: Venous blod sample
Regular venous blood sample withdrawn from the laboratory
Device: CHEMPAQ
Capillary blood sample analyzed by CHEMPAQ
|
- Pain sensation [ Time Frame: Monthly for four months ]Pain sensation was measured using a visual analog scale (VAS)
- The benefits of CHEMPAQ [ Time Frame: Monthly for four months ]Caregivers and patients were asked about the benefits of using CHEMPAQ for hematological clozapine monitoring.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Treated with clozapine
- Compliant with blood monitoring
- Willing to give informed consent
Exclusion Criteria:
- Prior case of agranulocytosis

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01138618
Denmark | |
Aalborg Psychiatric Hospital | |
Aalborg, Denmark, 9000 | |
Psychiatric Center Aarhus | |
Aarhus, Denmark, 8240 | |
Psychiatric Center Copenhagen | |
Copenhagen, Denmark | |
Psychiatric Centre Esbjerg | |
Esbjerg, Denmark | |
Psychiatric Center Roskilde | |
Greve, Denmark, 2670 | |
Psychiatric Center Odense | |
Odense, Denmark, 5000 |
Principal Investigator: | Jimmi Nielsen, MD | Aalborg Psychiatric Hospital, Aarhus University Hospital |
Publications:
Responsible Party: | University of Aarhus |
ClinicalTrials.gov Identifier: | NCT01138618 History of Changes |
Other Study ID Numbers: |
1.5 - 01 MARCH2010 |
First Posted: | June 7, 2010 Key Record Dates |
Last Update Posted: | November 7, 2011 |
Last Verified: | November 2011 |
Keywords provided by University of Aarhus:
Clozapine hematological monitoring CHEMPAQ Granulocytes WBC |
Additional relevant MeSH terms:
Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders Clozapine Serotonin Antagonists Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
Physiological Effects of Drugs Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs GABA Antagonists GABA Agents |